CBS 2019
CBSMD教育中心
中 文

科学研究

Abstract

Recommended Article

INTERMACS Profiles and Outcomes Among Non–Inotrope-Dependent Outpatients With Heart Failure and Reduced Ejection Fraction Economic and Quality-of-Life Outcomes of Natriuretic Peptide–Guided Therapy for Heart Failure Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced Cardiac Structural Changes After Transcatheter Aortic Valve Replacement: Systematic Review and Meta-Analysis of Cardiovascular Magnetic Resonance Studies The Year in Cardiovascular Medicine 2020: Valvular Heart Disease: Discussing the Year in Cardiovascular Medicine for 2020 in the field of valvular heart disease is Professor Helmut Baumgartner and Dr Javier Bermejo. Mark Nicholls reports Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial Clinical Outcomes Following Intravascular Imaging-Guided Versus Coronary Angiography-Guided Percutaneous Coronary Intervention With Stent Implantation: A Systematic Review and Bayesian Network Meta-Analysis of 31 Studies and 17,882 Patients A volumetric intravascular ultrasound comparison of early drug-eluting stent thrombosis versus restenosis

Original Research

JOURNAL:CBSMD Article Link

无复流现象

CBSMD

Pre-reading

2001年,Eeckhout和Kern将无复流现象(No-Flow Phenomenon)定义为冠状动脉循环中某一特定血管节段虽心肌灌注不足,但无机械性血管阻塞(mechanical vessel obstruction)冠状动脉造影证据。经皮冠状动脉介入治疗支架置入后在明确没有可见残余狭窄后,术者将首要关注冠状动脉血流,若发生无复流现象,或将进一步影响预后及左心室重构,增加不良心脏事件的风险。因此熟知可预防无复流现象的策略、药物(冠状动脉内注射腺苷intracoronary adenosine, 硝普钠nitropusside)和非药物(低体温法induced hypothermia)等干预法对提高介入质量、改善患者预后的重要性不言而喻。